Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Camizestrant |
Synonyms | |
Therapy Description |
Camizestrant (AZD9833) is a selective degrader of estrogen receptor, which leads to growth inhibition of ER-positive tumors (Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 1024-1024). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Camizestrant | AZD-9833|AZD9 833|AZD9833|AZ-14066724 | Hormone - Anti-estrogens 24 | Camizestrant (AZD9833) is a selective degrader of estrogen receptor, which leads to growth inhibition of ER-positive tumors (Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 1024-1024). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04588298 | Phase II | Camizestrant | A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer (SERENA-3) | Recruiting | 3 | |
NCT03616587 | Phase I | Camizestrant Camizestrant + Palbociclib Camizestrant + Everolimus | Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer (SERENA-1) | Recruiting | USA | ESP | 1 |
NCT04214288 | Phase II | Camizestrant Fulvestrant | A Comparative Study of AZD9833 Versus Fulvestrant in Women With Advanced ER-Positive HER2-Negative Breast Cancer (SERENA-2) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | 9 |